肠源性短链脂肪酸在肺部疾病中的作用研究进展  

Research progress on the role of gut-derived short-chain fatty acids in pulmonary diseases

作　　者：朴光宇 陈榕[1] 孟庆涛[2] PIAO Guang-yu;CHEN Rong;MENG Qing-tao(Department of Anesthesiology,Renmin Hospital of Wuhan University,the First Clinical College of Wuhan University,Wuhan 430060,Hubei,China)

机构地区：[1]武汉大学人民医院(武汉大学第一临床学院)麻醉科,湖北武汉430060 [2]武汉大学人民医院(武汉大学第一临床医学院)东院区麻醉科,湖北武汉430000

出　　处：《广东医学》2024年第10期1350-1356,共7页Guangdong Medical Journal

基　　金：国家自然科学基金项目(82172155,82202410)。

摘　　要：短链脂肪酸是参与免疫调控的关键调节因子,而短链脂肪酸水平变化受肠道微生物群组成的影响。肠道微生物源性的短链脂肪酸不仅可以改善肠道炎症性疾病,还可通过多种机制促进肠道和肺脏之间的双向交流,这种双向交流被定义为微生物-肠-肺轴。本文主要针对短链脂肪酸、肠道微生物群、微生物-肠-肺轴紊乱对肺部疾病发病的影响,以及短链脂肪酸的前沿研究进行综述,旨在为临床研究者提供思路。Short-chain fatty acids(SCFAs)are key regulatory factors involved in immune modulation,and their levels are influenced by the composition of the gut microbiota.Gut microbiota-derived SCFAs not only improve inflammatory diseases of the intestine but also facilitate bidirectional communication between the gut and the lungs through various mechanisms.This bidirectional communication is defined as the microbiome-gut-lung axis.This review focuses on the impact of SCFAs,gut microbiota,and dysregulation of the microbiome-gut-lung axis on the pathogenesis of lung diseases,as well as cutting-edge research on SCFAs,aiming to provide insights for clinical researchers.

关 键 词：短链脂肪酸 肠道微生物群 微生物-肠-肺轴 慢性阻塞性肺疾病 哮喘 益生菌治疗 

分 类 号：R563.9[医药卫生—呼吸系统] Q547[医药卫生—内科学]